We have identified for the first-time distinct gut microbiome profiles associated with post-acute COVID-19 syndrome, more commonly known as “long COVID”.
These distinct gut microbial signatures can be used to predict the risk of developing long COVID and diagnose long COVID in patients with persistent symptoms after the acute infection. This is the world’s first study to demonstrate the gut microbiota as a key determinant of long COVID
In order to help citizens fend off the epidemic and recover from COVID-19 and sequelae as soon as possible, we developed a non-invasive stool test for the diagnosis and risk prediction of "Long COVID" based on the fecal microbiome, thereby providing evidence for appropriate treatments or interventions.
First Asia-based, leading International Microbiome Innovation Centre.
Pioneering microbiome research leading to scientific discoveries and clinical applications of gut microbiota has set foot in the newly founded Microbiota I-Center (MagIC) in Hong Kong. Together with top-notch researchers, the center will focus on utilizing the human gut microbiome for the development of novel microbial biomarkers and personalized microbiome therapeutics. This approach sets a new frontier for the pharmaceutical, healthcare, and food industries in Hong Kong.